FORT WORTH, Texas, June 16, 2011 /PRNewswire/ -- Wound Management Technologies, Inc., (OTCQB: WNDM | WNDM.PK) a leader in advanced wound care solutions, today announced that Company President Deborah Jenkins Hutchinson will present a corporate update at the National Investment Banking Association (NIBA) conference on June 16th and 17th to be held at the St. Regis Atlanta Hotel in Atlanta, Georgia.
WNDM will update conference attendees with a mid-year status report of the following topics:
- Progress Towards Meeting Revenue and Income Targets For 2011 and Beyond
- Commercial and Government Channel Sales of CellerateRX®
- Professional and Direct-To-Consumer Sales
- New Domestic and International Sales & Distribution Agreements
- New Product Currently in Development
The National Investment Banking Association, Inc. (NIBA) is the only national not-for-profit trade association of regional and independent brokerages, investment banking firms, and related capital market service providers. The NIBA Conference provides Association Members and attendees a forum for industry professionals to exchange ideas and information. In light of new regulations and changes that have been proposed by Congress and the Securities and Exchange Commission, this is an important opportunity for Members to collectively voice their positions on issues that could severely impact the industry.
The presentation will be on Thursday morning followed by two breakout sessions on Thursday afternoon and Friday morning. More information about NIBA Atlanta can be viewed on the Conference’s website, http://nibanet.org, or under the Upcoming Events tab on http://www.wmgtech.com. Lastly, the status report presentation will be viewable on the website in “Investor Presentations” under the Investor Relations tab.
About Wound Management Technologies, Inc.
Wound Management Technologies, Inc. is an emerging commercial stage company with its primary products in the $5B worldwide advanced wound care market. Wound Management’s primary focus is the distribution of its unique, patented collagen product, CellerateRX®, which is FDA cleared and reimbursable under Medicare Part B. Wound Management has other advanced biotech products in development including a patented resorbable bone wax line that is in late stages of development, as well as a subsidiary focused on technology for secure healthcare data collaboration and storage. More information can be found on the company’s web sites: http://www.wmgtech.com and http://www.celleraterx.com.
Follow us on:FACEBOOK | TWITTER | LINKEDIN
Safe Harbor Statement:
The statements in the press release that relate to the company’s expectations with regard to the future impact on the company’s results from new products in development and any other statements not constituting historical facts are “forward-looking statements,” within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company’s actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company’s operations, current and future performance and financial condition. These items involve risks, contingencies and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties detailed in the Company’s SEC filings, which could cause the company’s actual operating results, performance or business plans or prospects to differ materially from those expressed in, or implied by these statements. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.
For Wound Management Technologies Shareholder Information please call (917) 974-9872 or visit http://www.wmgtech.com
For Further Information:
Shareholder Relations-Communications (917) 974-9872
SOURCE Wound Management Technologies, Inc.
